EX-10.1
from 10-Q
22 pages
Sio Gene Therapies Inc. 2015 Equity Incentive Plan Adopted by the Board of Directors: March 18, 2015 Approved by the Sole Member: March 18, 2015 Amended by the Board of Directors: May 19, 2015 Approved by the Stockholders: May 19, 2015 Amended and Restated by the Board of Directors: June 1, 2017 Approved by the Stockholders: August 18, 2017 Amended and Restated by the Board of Directors: October 1, 2020 Amended and Restated by the Board of Directors: August 2, 2021 Approved by the Stockholders: September 23, 2021 Termination Date: March 17, 2025
12/34/56
EX-10.1
from S-8 POS
22 pages
Sio Gene Therapies Inc. 2015 Equity Incentive Plan Adopted by the Board of Directors: March 18, 2015 Approved by the Sole Member: March 18, 2015 Amended by the Board of Directors: May 19, 2015 Approved by the Shareholders: May 19, 2015 Amended and Restated by the Board of Directors: June 1, 2017 Approved by the Shareholders: August 18, 2017 Amended and Restated by the Board of Directors: October 1, 2020 Termination Date: March 17, 2025
12/34/56
EX-10.2
from 10-Q
2 pages
July 23, 2018 Jerel a Banks, M.D., PH.D. Executive Chairman Benitec Biopharma Limited Suite 1201, 99 Mount Street North Sydney Nsw 2060 Australia Re: Amendment No. 1 to License and Collaboration Agreement Between Axovant Sciences Gmbh and Benitec Biopharma Limited. Accepted and Agreed for Axovant Sciences Gmbh: By: /S/ Mark Altmeyer Mark Altmeyer President & COO, Axovant Sciences Gmbh Accepted and Agreed for Benitec Biopharma Limited: By: /S/Peter Francis Name: Peter Francis Title: Director By: /S/Megan Boston Name: Megan Boston Title: Executive Director [***] = Certain Confidential Information Omitted 1
12/34/56
